Company Profile

Abceutics Inc
Profile last edited on: 9/28/2022            CAGE: 8PYU1            UEI: WN1QJMG5ZNC5

Enabling better cancer treatments
Year Founded
2020
1st Awd Year
2021
Latest Award
2021
Program Status
Active
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

701 Ellicott Street
Buffalo, NY 14203
   (716) 531-6837
   abceutics.nguyen@gmail.com
   www.abceuticsinc.com/
Multiple Locations:   
Congressional District:   26
County:   Erie

Public Profile

Working on the cutting-edge of biotechnology, the highly skilled and long-time experienced team assembled by Abceutics Inc are structured around offering solution to improve ADC technology. An area of primary focus of the very young firm is development of the first in a series of new drugs -- called payload-binding selectivity enhancers (PBSEs) -- that aim to improve the safety and efficacy of certain cancer drugs.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
1-4
Revenue Range
Less than .5M
VC funded?
No
Public/Private
Privately Held
Stock Info
---
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount Project Title
2021 1 NIH $168,038
Lead Optimization and Evaluation of Anti-SN38 Payload Binding Selectivity Enhancers

Key People / Management

  Joseph Balthasar -- Co-founder and President

  Larry C Wienkers -- Co-founder and Chief Scientific Officer

SBIR firms in the news

There are no news available.